Primary IOL implantation is successful in children under 2 years of age

Article

The implantation of intraocular lenses (IOL) is a safe and effective option for visual rehabilitation in children under 2 years of age, according to findings published in the British Journal of Ophthalmology.

The implantation of intraocular lenses (IOL) is safe and effective option for visual rehabilitation in children under 2 years of age, according to findings published in the British Journal of Ophthalmology.

Dr Ramesh Kekunnaya et al., Jasti V Ramanamma Children's Eye Care Center, Hyderabad, India, collected data from 120 eyes of 80 children with congenital/developmental cataract who underwent surgery between January 2006 and December 2007. Of the 120 eyes, 31 were operated on before they were 6 months of age and 89 eyes were operated on after 6 months of age. Rigid polymethylmethacrylate lenses were implanted in 30 eyes and acrylic hydrophobic foldable lenses were implanted in 90 eyes.

Five eyes demonstrated increased anterior chamber inflammation, 8 eyes experienced opacification of the visual axis, 2 eyes had decentration of IOL, 4 eyes experienced pigment dispersion on IOL and posterior synechiae were recorded in 5 eyes.

At the last follow-up there were no cases of glaucoma and no cases of endophthalmitis and retinal detachment. It was concluded that the implantation of IOLs in children below 2 years of age is a viable method for visual performance enhancement.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.